Home » Guillain-Barré Risk Low to Nonexistent After H1N1 Vaccine

Guillain-Barré Risk Low to Nonexistent After H1N1 Vaccine

July 14, 2011

If there was an elevated risk of developing Guillain-Barré syndrome after receiving an adjuvanted, monovalent influenza A (H1N1) vaccine during the 2009 pandemic, it wasn’t raised by much, a European study showed.
MedPage Today

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Guillain-Barré Risk Low to Nonexistent After H1N1 Vaccine

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Amgen to Buy Five Prime Therapeutics for $1.9 Billion

Abbott Secures EUA for COVID-19 Combination Test

Eli Lilly’s COVID-19 Antibody and Combo Therapy Gets Positive EMA Recommendation

FDA Grants EUA for Adaptive Biotechnologies’ T Cell COVID-19 Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements